Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06176885 |
TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-12-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT02537418 |
TitleDurvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | 阶段
第 1 阶段
|
Date Added 2015-09-01 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
durvalumab, Tremelimumab, Imfinzi |
标签
MSS/ MMRp
|
| NCT ID NCT02888743 |
TitleDurvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | 阶段
第二阶段
|
Date Added 2016-09-05 |
地点
Arizona, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States 加拿大 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
durvalumab, Tremelimumab |
标签
MSS/ MMRp
|
| NCT ID NCT03911557 |
TitleDurvalumab和Tremelimumab联合治疗体细胞高突变复发性实体瘤 | 阶段
第二阶段
|
Date Added 2019-04-11 |
地点
Kentucky, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Durvalumab和Tremelimumab |
标签
MSS/ MMRp
|
| NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-07-29 |
地点
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Pembrolizumab, WTX-124 |
标签
MSI-H/ MMRd
|
| NCT ID NCT03310008 |
TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | 阶段
第 1 阶段
|
Date Added 2017-10-16 |
地点
比利时
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NKR-2 cells |
标签
MSS/ MMRp
|
| NCT ID NCT05493683 |
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-08-09 |
地点
China,China,China,China,China,China
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Disitamab vedotin, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | 阶段
第二阶段
|
Date Added 2023-03-15 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Atezolizumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT03668431 |
Title达拉非尼 + 曲美替尼 + PDR001 在结直肠癌中的应用 | 阶段
第二阶段
|
Date Added 2018-09-12 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03566355 |
TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer | 阶段
不适用
|
Date Added 2018-06-25 |
地点
大韩民国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
